

Status report for phase 2 study

SpectraCure has conducted a Phase 1 clinical trial for the treatment of patients with recurrent prostate cancer with the company's technology for photodynamic therapy (PDT). As previously announced, at the end of 2018, the company entered the final stage of planning for a subsequent phase 2 study. In early 2019, SpectraCure renewed certain contracts and planned the continuation study along with the partner hospitals, Princess Margaret Cancer Centre in Toronto, University College London Hospital in London, and the University of Pennsylvania Hospital in Philadelphia.

On 17th March, a meeting was held with the investigators in the study, to review the results of the Phase 1 study and to complete the planning for the continued clinical program. Screening and recruitment of patients to be included in the study has already begun and patient treatments will start in early April.

"Now we look forward to start the Phase 2 study together with our clinical partners" - says Masoud Khayyami, CEO.

The purpose of the Phase 2 study is to show that the method is safe to use, and that it has a clinical effect, with a larger statistical basis than in the Phase 1 study.

For further information, contact:

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46-(8)-503 000 50.

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region